<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580994</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1417-LCG</org_study_id>
    <secondary_id>2014-003090-42</secondary_id>
    <nct_id>NCT02580994</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Untreated Extensive SCLC</brief_title>
  <acronym>REACTION</acronym>
  <official_title>REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme (MSD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial
      investigating the activity of pembrolizumab in combination with standard chemotherapy in
      Extensive Disease (ED)-SCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, two armed, controlled, and randomized phase II trial
      investigating the activity of pembrolizumab in combination with standard chemotherapy in
      ED-SCLC.

      Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the
      informed consent, and then centrally randomized 1:1 to the experimental arm (Arm A) and the
      control arm (Arm B).

      Cross-over at the time of disease progression will be allowed for arm B only.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Small Cell Lung Cancer (SCLC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles of cis/carboplatin and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion at the dose of 200 mg on day 1 every 3 weeks</description>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis/carboplatin and etoposide</intervention_name>
    <description>Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3</description>
    <arm_group_label>Pembrolizumab + chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Platinol, Paraplatin and Etopophos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed SCLC

          -  Extended disease according to the criteria of the Veteran's Administration - Lung
             Cancer Group (VALG): disease extended beyond a hemithorax and the supraclavicular node
             area. Pleural involvement will be considered as extended disease

          -  Assessment of adequate tissue availability for Program Cell Death-Ligand 1 (PD-L1)
             immunohistochemistry testing

          -  Before patient registration, written informed consent must be given according to
             International Conference of Harmonization-Good Clinical Practice (ICH-GCP), and
             national/local regulations

          -  Tumor assessment performed within 10 days before randomization. Patient may or may not
             have measurable disease

          -  Previous palliative brain radiotherapy is allowed if terminated at least 3 weeks
             before randomization

          -  Partial or complete response according to RECIST (Response Evaluation Criteria in
             Solid Tumors) 1.1 after 2 cycles of any platinum-based induction chemotherapy regimen

          -  Adequate hematopoietic, hepatic and renal function within 10 days before randomization
             defined as follows:

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10E9/L, Hemoglobin (Hb) ≥ 9 g/dL and
                  platelet count ≥ 100 x 10E9/L

               -  Serum creatinine clearance ≥ 60 mL/min as calculated with Cockcroft-Gault formula

               -  Bilirubin ≤ 1.5 x Upper Limit Normal (ULN), Alanine Aminotransferase (ALT) (SGTP)
                  and Aspartate Transaminase (AST) (SGOT) ≤ 3 x ULN

               -  International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x ULN unless
                  subject is receiving anticoagulant therapy as long as PT or PTT is within
                  therapeutic range of intended use of anticoagulants

               -  Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless subject is
                  receiving anticoagulant therapy as long as a PTT is within therapeutic range of
                  intended use of anticoagulants N.B. Lactate Dehydrogenase (LDH) level assessment
                  is mandatory for randomization

          -  Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy
             test within 72 hours before randomization

          -  Patients of childbearing / reproductive potential should use adequate birth control
             measures, as defined by investigator, during the study treatment period and for at
             least 120 days after the last study treatment. A highly effective method of birth
             control is defined as those which result in low failure rate (i.e. less than 1% per
             year) when used consistently and correctly.

          -  Female subjects who are breast feeding should discontinue nursing before randomization
             and until 120 days after the last study treatment

        Exclusion Criteria:

          -  Prior systemic therapy for SCLC; previous treatment with platinum and etoposide
             concomitant with radiotherapy (RT) for limited disease is allowed if terminated at
             least 1 year before patient randomization

          -  known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
             Patients with previously treated brain metastases may participate provided they are
             stable (i.e. without evidence of progression by imaging and any neurologic symptoms
             have returned to baseline), have no evidence of new or enlarging brain metastases, and
             have not received steroids for at least 7 days before randomization

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 3-4 (at
             registration) (patients who are judged by the investigator to be PS 2 due to primary
             disease are the only PS 2 patients who are eligible)

          -  ECOG PS 2-4 (at randomization)

          -  Less than 3 month life expectancy

          -  History of interstitial lung disease (ILD) or a history of (non-infectious)
             pneumonitis that required oral or IV steroids (other than Chronic Obstructive
             Pulmonary Disease [COPD] exacerbation) or current pneumonitis or current evidence of
             ILD

          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs), any
             replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment and is allowed

          -  Previous allogeneic tissue/solid organ transplant

          -  Active infection requiring therapy

          -  Known history of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies
             positive). No known active Hepatitis B or C. Active Hepatitis B is defined as a known
             positive HBsAg results. Active Hepatitis C is defined by a known positive Hep C Ab
             result and known quantitative Hepatitis C Virus (HCV) RNA results greater than the
             lower limits of detection of the assay

          -  Ongoing grade ≥ 2 peripheral neuropathy

          -  Prior treatment with platinum, anti-PD-1, anti-PD-L1/2, anti interleukin-7
             receptor-alpha (anti-CD127), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) modulators

          -  Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in
             the 3 days before randomization:

          -  Corticosteroid use on study for management of pembrolizumab Events of Clinical
             Interest (ECIs), as pre-medication for the administration of chemotherapies, and/or a
             pre-medication for contrast allergies/reactions is allowed

          -  Daily prednisone at doses of 5-7.5 mg is allowed as an example of replacement therapy.
             Equivalent hydrocortisone doses are also permitted if administered as a replacement
             therapy

          -  Prior use of live vaccines within 30 days before randomization. Examples of live
             vaccines include, but are not limited to, the following : measles, mumps, rubella,
             chicken pox, shingles, yellow fever, influenza A virus subtype (H1N1) flu, rabies,
             Bacillus Calmette-Guerin (BCG), and typhoid vaccine

          -  Presence of any clinical, psychological, familial, sociological or geographical
             condition potentially hampering compliance with the study protocol and follow-up
             schedule; those conditions should be discussed with the patient before registration in
             the trial

          -  Concurrent treatment with any investigational agent within 4 weeks before
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Besse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, Villejuif, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Menis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Oncologico Veneto IRCCS, Padova, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kin Jip Cheung</last_name>
    <phone>+32 2 774 16 07</phone>
    <email>kin-jip.cheung@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University Faculty of Medicine - Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11331</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omar Abdel-Rahman</last_name>
    </contact>
    <investigator>
      <last_name>Omar Abdel-Rahman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rabab Gaafar</last_name>
    </contact>
    <investigator>
      <last_name>Rabab Gaafar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Avignon - Hopital Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Cloarec</last_name>
      <email>cloarec.nicolas@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Cloarec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Robinet</last_name>
      <email>gilles.robinet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Robinet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radji Gervais</last_name>
      <email>r.gervais@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Radji Gervais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Intercommunal De Creteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Monnet, MD</last_name>
      <email>Isabelle.Monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Monnet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Fayette</last_name>
      <email>jerome.fayette@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jerome Fayette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Greillier</last_name>
      <email>laurent.greiller@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Greillier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Decroisette</last_name>
      <email>cdecroisette@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal Decroisette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Paris - Hopital Avicenne</name>
      <address>
        <city>Paris</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Duchemann</last_name>
      <email>boris.duchemann@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Boris Duchemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schott</last_name>
      <email>rschott@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Roland Schott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Besse</last_name>
      <email>Benjamin.besse@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Besse, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Banna</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Banna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Croce e Carle General Hospital</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ida Colantonio</last_name>
      <email>colantonio.i@ospedale.cuneo.it</email>
    </contact>
    <investigator>
      <last_name>Ida Colantonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Livi</last_name>
    </contact>
    <investigator>
      <last_name>Lorenzo Livi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo De Marinis</last_name>
      <email>filippo.demarinis@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Filippo De Marinis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Luciani</last_name>
      <email>andrea.luciani@asst-santipaolocarlo.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Luciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Luigi Gonzaga - Universita Di Torino</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello</last_name>
      <email>silvia.novello@unito.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Novello, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Santa Maria della Misericordia&quot; di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Follador</last_name>
      <email>alessandro.follador@asuiud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Follador, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Bria</last_name>
      <email>emilio.bria@univr.it</email>
    </contact>
    <investigator>
      <last_name>Emilio Bria, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Steele</last_name>
      <email>Nicola.Steele@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nicola Steele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaele Califano</last_name>
      <email>raffaele.califano@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Raffaele Califano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alastair Greystoke</last_name>
      <email>alastair.greystoke@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alastair Greystoke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Young</last_name>
      <email>r.j.young@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Robin Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust - Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Cave</last_name>
      <email>Judith.Cave@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Judith Cave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Sutton, Surrey</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaishree Bhosle</last_name>
      <email>Jaishree.Bhosle@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jaishree Bhosle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended Disease Small Cell Lung Cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>randomized</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>cross-over</keyword>
  <keyword>etoposide</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <keyword>rechallenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

